Quantitative measurement of HER2 expression to subclassify ERBB2 unamplified breast cancer

Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue

(2022) Aileen I. Fernandez et al.   JAMA Oncology

Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer

(2021) Hope S. Rugo et al.   JAMA Oncology

Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Study

(2020) Shanu Modi et al.   JOURNAL OF CLINICAL ONCOLOGY

HER2-Low Breast Cancer: Pathological and Clinical Landscape

(2020) Paolo Tarantino et al.   JOURNAL OF CLINICAL ONCOLOGY

Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial

(2020) Cristina Saura et al.   JOURNAL OF CLINICAL ONCOLOGY

Analysis of Immune Checkpoint Drug Targets and Tumor Proteotypes in Non-Small Cell Lung Cancer

(2020) Daniel C. Liebler et al.   Scientific Reports

The Latest Research and Development into the Antibody–Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy

(2019) Takashi Nakada et al.   CHEMICAL & PHARMACEUTICAL BULLETIN

Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer

(2019) Rashmi K. Murthy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update

(2018) Antonio C. Wolff et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

FDA Approval Summary: Pertuzumab for adjuvant treatment of HER2-positive early breast cancer

(2018) Lynn J. Howie et al.   CLINICAL CANCER RESEARCH

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

(2018) Gunter von Minckwitz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Quantitative Mass Spectrometry Analysis of PD-L1 Protein Expression,N-glycosylation and Expression Stoichiometry with PD-1 and PD-L2 in Human Melanoma

(2017) Carlos A. Morales-Betanzos et al.   MOLECULAR & CELLULAR PROTEOMICS

QuPath: Open source software for digital pathology image analysis

(2017) Peter Bankhead et al.   Scientific Reports

Quantitative measurement of cancer tissue biomarkers in the lab and in the clinic

(2014) Daniel E Carvajal-Hausdorf et al.   LABORATORY INVESTIGATION

Single-Cell Quantitative HER2 Measurement Identifies Heterogeneity and Distinct Subgroups within Traditionally Defined HER2-Positive Patients

(2013) Matthew D. Onsum et al.   AMERICAN JOURNAL OF PATHOLOGY

Effect of Ischemic Time, Fixation Time, and Fixative Type on HER2/neu Immunohistochemical and Fluorescence In Situ Hybridization Results in Breast Cancer

(2011) Neda A. Moatamed et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Human epidermal growth factor receptor 2 (HER2) immunoreactivity: specificity of three pharmacodiagnostic antibodies

(2011) Anne-Sofie Schrohl et al.   HISTOPATHOLOGY

Quantitative assessment shows loss of antigenic epitopes as a function of pre-analytic variables

(2011) Yalai Bai et al.   LABORATORY INVESTIGATION

Skyline: an open source document editor for creating and analyzing targeted proteomics experiments

(2010) Brendan MacLean et al.   BIOINFORMATICS

FDA Drug Approval Summary: Lapatinib in Combination with Capecitabine for Previously Treated Metastatic Breast Cancer That Overexpresses HER-2

(2008) Q. Ryan et al.   ONCOLOGIST